Simvastatin Preferentially Targets FLT3/ITD Acute Myeloid Leukemia by Inhibiting MEK/ERK and p38-MAPK Signaling Pathways

• Main Authors: Genhong Li (Author), Jingwei Yao (Author), Zhen Lu (Author), Lian Yu (Author), Qinwei Chen (Author), Lihong Ding (Author), Zhihong Fang (Author), Yin Li (Author), Bing Xu (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2023-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background The FLT3/ITD mutation exists in many acute myeloid leukemia (AML) patients and is related to the poor prognosis of patients. In this study, we attempted to evaluate the antitumor activity of simvastatin, a member of the statin class of drugs, in vitro and in vivo models of FLT3/I...